IDYA vs KURA
IDYA: IDEAYA Biosciences is a clinical-stage precision medicine company focused on discovering and developing targeted synthetic lethality therapies for oncology. KURA: A clinical-stage oncology biopharmaceutical company developing targeted, small-molecule precision therapies for cancer patients.
Side-by-side fundamentals
| Metric | IDYA | KURA | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $36.06 | $10.52 | |
| Market cap | $3.5B | $936M | |
| Net margin FY2025, SEC XBRL | -52.0% | -412.9% | IDYA higher |
| Operating margin FY2025, SEC XBRL | -72.8% | -449.9% | IDYA higher |
| ROE FY2025, SEC XBRL | -11.1% | -160.0% | IDYA higher |
| ROA FY2025, SEC XBRL | -10.2% | -37.7% | IDYA higher |
| Debt / equity as of 2026-09-02 | 0.00 | 0.09 | IDYA lower |
| Revenue growth (YoY) as of 2026-09-02 | +3118.1% | +29.5% | IDYA higher |
| Revenue CAGR (3y) SEC XBRL | +62.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 0.97 | 1.04 | |
| 1-year return as of 2026-10-08 close | +34.4% | +4.4% | IDYA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.